Christine Lasset

5.1k total citations · 1 hit paper
99 papers, 3.7k citations indexed

About

Christine Lasset is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Christine Lasset has authored 99 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 23 papers in Epidemiology and 22 papers in Molecular Biology. Recurrent topics in Christine Lasset's work include Neuroblastoma Research and Treatments (18 papers), Genetic factors in colorectal cancer (14 papers) and Colorectal Cancer Screening and Detection (9 papers). Christine Lasset is often cited by papers focused on Neuroblastoma Research and Treatments (18 papers), Genetic factors in colorectal cancer (14 papers) and Colorectal Cancer Screening and Detection (9 papers). Christine Lasset collaborates with scholars based in France, Italy and Switzerland. Christine Lasset's co-authors include Sylvie Négrier, Bernard Escudier, Thierry Philip, Alain Ravaud, Christine Chevreau, Jean‐Yves Douillard, J. Savary, Franck Chauvin, Mireille Mousseau and A. Mercatello and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christine Lasset

92 papers receiving 3.6k citations

Hit Papers

Recombinant Human Interleukin-2, Recombinant Human Interf... 1998 2026 2007 2016 1998 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
    1998 742 citations Sylvie Négrier, Bernard Escudier et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christine Lasset France 31 1.4k 1.3k 1.3k 977 633 99 3.7k
Alex McMillan United States 33 861 0.6× 944 0.7× 712 0.5× 716 0.7× 256 0.4× 57 3.5k
Najat C. Daw United States 40 1.4k 1.1× 1.2k 0.9× 2.7k 2.1× 509 0.5× 507 0.8× 154 4.7k
Xiaopan Yao United States 30 906 0.7× 919 0.7× 676 0.5× 422 0.4× 814 1.3× 68 3.7k
Christophe Bergeron France 44 2.1k 1.6× 1.3k 1.0× 2.5k 1.9× 542 0.6× 1.5k 2.3× 174 5.4k
Scott I. Bearman United States 28 1.1k 0.8× 1.7k 1.3× 1.5k 1.1× 819 0.8× 159 0.3× 59 5.2k
Marcio H. Malogolowkin United States 37 1.8k 1.3× 1.0k 0.8× 1.1k 0.9× 444 0.5× 494 0.8× 124 4.2k
Uta Dirksen Germany 38 1.5k 1.1× 1.5k 1.1× 3.6k 2.7× 776 0.8× 659 1.0× 190 5.8k
Gian Luca De Salvo Italy 39 660 0.5× 1.7k 1.2× 1.5k 1.1× 909 0.9× 319 0.5× 135 4.3k
Jan de Kraker Netherlands 43 3.4k 2.5× 655 0.5× 1.9k 1.5× 689 0.7× 1.5k 2.3× 147 5.6k
Laura C. Bowman United States 42 1.5k 1.1× 2.3k 1.7× 972 0.7× 473 0.5× 1.7k 2.8× 107 5.8k

Countries citing papers authored by Christine Lasset

Since Specialization
Citations

This map shows the geographic impact of Christine Lasset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Lasset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Lasset more than expected).

Fields of papers citing papers by Christine Lasset

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Lasset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Lasset. The network helps show where Christine Lasset may publish in the future.

Co-authorship network of co-authors of Christine Lasset

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Lasset. A scholar is included among the top collaborators of Christine Lasset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Lasset. Christine Lasset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bonadona, Valérie, et al.. (2025). Cancer risks in Lynch syndrome carriers: a systematic review and meta-analysis. JNCI Journal of the National Cancer Institute.
2.
Poulard, Coralie, Julien Jacquemetton, Loay Kassem, et al.. (2023). Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα + breast cancer. EMBO Molecular Medicine. 15(8). e17248–e17248. 9 indexed citations
3.
Jenkins, Mark A., James G. Dowty, Driss Ait Ouakrim, et al.. (2014). Short-Term Risk of Colorectal Cancer in Individuals With Lynch Syndrome: A Meta-Analysis. Journal of Clinical Oncology. 33(4). 326–331. 24 indexed citations
4.
Lasset, Christine, et al.. (2014). Practices and opinions regarding HPV vaccination among French general practitioners: evaluation through two cross-sectional studies in 2007 and 2010. International Journal of Public Health. 59(3). 519–528. 13 indexed citations
5.
6.
Anczuków, Olga, Monique Buisson, Mélanie Léoné, et al.. (2012). BRCA2 Deep Intronic Mutation Causing Activation of a Cryptic Exon: Opening toward a New Preventive Therapeutic Strategy. Clinical Cancer Research. 18(18). 4903–4909. 52 indexed citations
7.
Dorval, Michel, Jocelyne Chiquette, Christine Lasset, et al.. (2011). Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. European Journal of Human Genetics. 19(5). 494–499. 13 indexed citations
8.
Voirin, Nicolas, David G. Cox, Sylvie Chabaud, et al.. (2009). Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. British Journal of Cancer. 101(4). 673–683. 165 indexed citations
9.
Lasset, Christine, et al.. (2007). Focus Group Approach for Developing Written Patient Information in Oncogenetics. Genetic Testing. 11(2). 193–197. 5 indexed citations
10.
Mancini, Julien, Catherine Noguès, Claude Adenis, et al.. (2006). Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. European Journal of Cancer. 42(7). 871–881. 39 indexed citations
11.
Négrier, Sylvie, Bernard Escudier, F. Gómez, et al.. (2002). Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie. Annals of Oncology. 13(9). 1460–1468. 273 indexed citations
12.
Eisinger, François, Marc Espié, Christine Lasset, et al.. (1998). La chimioprévention du cancer du sein. Bulletin du Cancer. 85(8). 1 indexed citations
13.
14.
Philip, Thierry, Ruth Ladenstein, Christine Lasset, et al.. (1997). 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Journal of Cancer. 33(12). 2130–2135. 74 indexed citations
15.
Mathieu, Pierre, Didier Frappaz, Franck Chauvin, et al.. (1996). A 5-year (1990–1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations. Early Human Development. 46(1-2). 177–196. 9 indexed citations
16.
Carrié, C., C. Mottolèse, Éric Bouffet, et al.. (1995). Non-metastatic childhood ependymomas. Radiotherapy and Oncology. 36(2). 101–106. 24 indexed citations
17.
Estève, Jacques, Louise Parker, Pascal Roy, et al.. (1995). Is neuroblastoma screening evaluation needed and feasible?. British Journal of Cancer. 71(6). 1125–1131. 31 indexed citations
18.
Ladenstein, Ruth, Christine Lasset, Pierre Biron, et al.. (1992). The impact of megatherapy on response and survival in high-risk Ewing's sarcoma. A report of the EBMT solid tumor registry. Bone Marrow Transplantation. 10(2). 20–20. 3 indexed citations
19.
Lasset, Christine, Olivier Hartmann, Guglielmo Dini, et al.. (1992). The Lyon and the Ebmt Data On Megatherapy (Mgt) in Neuroblastoma Followed by Bone-Marrow Rescue. Bone Marrow Transplantation. 10(2). 14–14. 2 indexed citations
20.
Philip, T, Olivier Hartmann, Charles S. August, et al.. (1988). Stage IV neuroblastoma alive progression free 17 months post-BMT are not cured. Bone Marrow Transplantation. 3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex McMillan Breakdown of academic impact, for papers by Najat C. Daw Breakdown of academic impact, for papers by Xiaopan Yao Breakdown of academic impact, for papers by Christophe Bergeron Breakdown of academic impact, for papers by Scott I. Bearman Breakdown of academic impact, for papers by Marcio H. Malogolowkin Breakdown of academic impact, for papers by Uta Dirksen Breakdown of academic impact, for papers by Gian Luca De Salvo Breakdown of academic impact, for papers by Jan de Kraker Breakdown of academic impact, for papers by Laura C. Bowman
Rankless by CCL
2026